Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

23 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Oxandrolone Articles

Savient restructures following generic appro

15 January 2007

Savient files patent suit against Sandoz

11 December 2006

Savient seeks European partner for first breakthrough gout treatment in 40 years

10 July 2006

B-TG's Oxandrin OKed In Russia

12 March 1998

US Corporate 1997 Year-End Results Round-Up

11 February 1998

"Highly Pleasing" 1996 Results At BTG

10 March 1997

FDA To Initiate Full Review Of Bio-Technology General's Oxandrin

4 November 1996

BTG's First Profitable Year

15 April 1996

BTG Launches Anabolic Steroid Oxandrin In The USA

4 December 1995

1994 Brings Israel's BTG Closer To Goals

3 July 1995

BTG Achieves First Quarter of Profitability

5 September 1994

hGH IN JAPAN BOOSTS BIOTECH GENERAL SALES

13 June 1994

BIO-TECHNOLOGY GENERAL RECEIVES APPROVAL

31 January 1994

WORLD PRODUCT NEWS IN BRIEF

24 January 1994

BIOTECH GENERAL LOSS DESPITE GOOD SALES GROWTH

22 November 1993

ISRAEL'S GYNEX AND USA'S BTG TO MERGE

21 June 1993

OXANDRIN AND ALCOHOLISM

10 May 1993

CLINICAL STUDY FOR OXANDRIN

5 April 1993

BIOT-TECHNOLOGY GENERAL TO ACQUIRE GYNEX

22 March 1993

GYNEX PRODUCT AIDS TURNER'S PATIENTS

8 June 1992

MORTALITY BENEFIT WITH GYNEX' OXANDRIN

17 February 1992

TREATMENT IND FOR GYNEX' OXANDRIN

6 January 1992

Showing 1-22 of 22 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Boehringer Ingelheim gets FDA warning letter on cGMP failures
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS